TECTONIC THERAPEUTIC, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
TECTONIC THERAPEUTIC, INC. (TECX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.26% for the 6-month period ending 2024-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-08-07
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 1.67%, a 165.08% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.63%, a 34.37% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 0.96%, a 62.06% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.53%, a 6.99% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.82%, a 54.66% increase from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.47%, a 208.75% increase from fiscal 2021.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.80%, a 5.26% increase from fiscal 2020.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.76%, a 63.64% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|
| 2024-06-30 | 4.26% 10-Q · filed 2025-08-07 | |||||
| 2023-12-31 | 3.82% 10-K · filed 2024-03-14 | |||||
| 2023-09-30 | 3.65% 10-Q · filed 2024-11-12 | 3.82% 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | 3.65% 10-Q · filed 2024-08-14 | 3.82% 10-Q · filed 2023-08-10 | ||||
| 2022-12-31 | 2.47% 10-K · filed 2024-03-14 | |||||
| 2022-09-30 | 1.80% 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | 1.80% 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | 1.67% 10-Q · filed 2023-05-11 | |||||
| 2021-12-31 | 0.80% 10-K · filed 2023-03-23 | |||||
| 2021-09-30 | 0.76% 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | 0.76% 10-Q · filed 2022-08-09 | |||||
| 2021-03-31 | 0.63% 10-Q · filed 2022-05-10 | |||||
| 2020-12-31 | 0.76% 10-K · filed 2022-03-17 | |||||
| 2020-09-30 | 0.84% 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | 0.88% 10-Q · filed 2021-08-05 | |||||
| 2020-03-31 | 0.96% 10-Q · filed 2021-05-13 | |||||
| 2019-12-31 | 2.09% 10-K · filed 2021-03-18 | |||||
| 2019-09-30 | 2.40% 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | 2.54% 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | 2.53% 10-Q · filed 2020-05-07 | |||||
| 2018-12-31 | 2.74% 10-K · filed 2020-03-16 | |||||
| 2018-09-30 | 2.81% 10-Q · filed 2018-11-13 | 2.73% 10-Q · filed 2019-11-07 | ||||
| 2018-06-30 | 2.73% 10-Q · filed 2019-08-08 | |||||
| 2018-03-31 | 2.72% 10-Q · filed 2019-05-13 | |||||
| 2017-12-31 | 1.93% 10-K · filed 2019-03-25 | |||||
| 2017-09-30 | 1.88% 10-Q · filed 2018-11-13 | 1.89% 10-Q · filed 2018-11-13 | ||||
| 2017-06-30 | 1.90% 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |